Close

Coherus BioSciences (CHRS), Baxalta (BXLT) Announce CHS-0214 Phase 3 Met Primary Endpoint in RA

January 11, 2016 6:48 AM EST Send to a Friend
Coherus BioSciences, Inc. (Nasdaq: CHRS) and Baxalta Incorporated (NYSE: BXLT) announced that CHS-0214, a proposed biosimilar of Enbrel® (etanercept), met ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login